Randomized Trialhigh evidence
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
The New England journal of medicine·September 4, 2025·PMID 40549887
Why it mattersThis study suggests a once-monthly incretin-based option may achieve clinically meaningful weight loss and glycemic improvement, which could be relevant for patients who prefer less frequent injections or have adherence challenges with weekly agents.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled